About ImmunityBio, Inc. - IBRX
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies to combat cancer and infectious diseases by working with the body's natural immune system. Their approach includes a variety of platforms such as immunomodulators and cell-based therapies.
What are ImmunityBio, Inc.'s core values and mission statement?
ImmunityBio, Inc. is a biotechnology company focused on developing therapies that activate the immune system to defeat cancers and infectious diseases. Its mission revolves around leveraging the body's natural immune defenses to create treatments with the goal of improving the lives of patients.
Who founded ImmunityBio, Inc. and when?
ImmunityBio, Inc. was founded by Dr. Patrick Soon-Shiong in 2014.
Who leads ImmunityBio, Inc.?
ImmunityBio, Inc. is led by Dr. Patrick Soon-Shiong, who founded the company and serves as its Chairman and CEO.
Where is ImmunityBio, Inc. located, and what is its base country?
ImmunityBio, Inc. is based in the United States, with its headquarters located in Culver City, California.
On which exchanges is ImmunityBio, Inc. traded?
ImmunityBio, Inc. is traded on the NASDAQ Stock Market under the ticker symbol IBRX.
ImmunityBio, Inc. (IBRX) Price Live Data
The live price of ImmunityBio, Inc. (IBRX) is $4.60, with a trading volume of 677,336 in the last 24 hours. Wrapstocks updates the IBRX price in real-time. ImmunityBio, Inc. is down -9.32% in the last 24 hours. The company has a live market cap of $3,083,522,560.00 and a supply of 670,330,991 IBRX stocks.
ImmunityBio, Inc. (IBRX) is traded on NASDAQ Stock Exchange, and currently, the market is open; trading will be paused in 5 hours and 18 minutes.